Cartesian Therapeutics, Inc. (RNAC) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Cartesian Therapeutics, Inc., formerly Selecta Biosciences, Inc., is a clinical-stage company, which is engaged in ribonucleic acid (RNA) cell therapies for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is an RNA-engineered chimeric antigen receptor T-cell therapy (rCAR-T) in Phase IIb clinical development for patients with generalized myasthenia gravis. Descartes-08 is designed to be an autologous anti-BCMA rCAR-T. Descartes-08 is in clinical development for autoimmune diseases, including Myasthenia gravis (MG), a chronic autoimmune disorder that causes disabling muscle weakness and fatigue. Its proprietary technology platform, RNA Armory, is designed to enable precision control and optimization of engineered cells for diverse cell therapies leveraging multiple modalities, including autologous, allogeneic, and in vivo transfection. Orphan Drug Designation by the United States Food and Drug Administration has granted Descartes-08 for the treatment of MG.
the bull case· 2
8
disclosed supplier and customer ties in SEC filings
sec filingsedgar5 of 6
recent reports where the move came in under the options implied range
earnings historyimplied vs realizedthe bear case· 2
3
of the funds on file reporting a position in RNAC
n-portas of Jun 30 '263 of 17
of the largest reporting managers cut their stake in the latest quarter
13fJun 30 '26Sides and captions by the model; every figure is ours. Built Sep 16 '26 for the Nov 12 '26 report. Not a forecast, not advice.
Of the 6 companies Cartesian Therapeutics, Inc. moves with most closely, none share its SEC classification.
Measured against 500 trading days of our own closes. Co-movement, not cause.
SIC 2834, Pharmaceutical Preparations, from each company's own filings. Largest first.
95 managers report a position worth $92.3M between them, and 15 of them hold 80% of it.
tall tick = annual report · 1 on record
Cartesian Therapeutics, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
High 8.20 at 3:45 pm ET, low 7.71 at 9:45 am ET.
RNAC (Cartesian Therapeutics, Inc.) has 5 disclosed suppliers and 3 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for its filing sentence; select again to open the company. Nearer the centre, the more the filings disclose. Extended: satellites hang off single companies, not bundled sectors.